期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

新型抗Her-2药物T-DM1 被引量：6

A novel HER2-targeted drug: T-DM1 antibody-drug conjugate
暂未订购
导出
摘要 T-DM1是新型抗体-药物偶联物,具有曲妥珠单抗类似的生物活性,可特异性的将强效抗微管药物DM1释放至Her-2过表达的肿瘤细胞内。T-DM1单药疗效优于拉帕替尼联合卡培他滨,有望成为Her-2阳性晚期乳腺癌的标准二线治疗药物。比较T-DM1与曲妥珠单抗联合紫杉类药物一线治疗晚期乳腺癌的试验正在进行中。该药是继曲妥珠单抗之后又一种全新的抗Her-2药物。美国FDA正式批准T-DM1作为治疗Her-2阳性晚期乳腺癌患者的药物。 T-DM1 is a novel antibody-drug conjugate that has similar biological activity with that of trastuzumab. T-DM1 specifically delivers DM1, the effective anti-microtubule drug, into the cytoplasm of tumor cells with HER2 overexpression. The efficacy of T-DM1 monotherapy is better than lapatinib in combination with capecitabine and T-DM and is expected to become the standard second-line treatment for HER2-positive advanced breast cancer drugs. Clinical trials that compare T-DM1 with trastuzumab joint taxane as the first-line of treatment for advanced breast cancer trials are currently being performed. T-DM1 is a brand new anti-HER2 drug after trastuzumab. U.S. FDA already approved T-DM1 as a drug for the treatment of HER2-positive advanced breast cancer patients.
作者 岳健 徐兵河
机构地区 北京协和医学院
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2013年第19期1203-1206,共4页 Chinese Journal of Clinical Oncology
关键词 T—DM1 乳腺癌 HER-2阳性 抗体-药物偶联物 T-DM1, breast cancer, HER2 positive, antibody-drug conjugate
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献25

  • 1Perou CM, Scrlie T, Eisen MB, et al. Molecular portraits of human breast tumours[J]. Nature, 2000, 406(6797):747-752.
  • 2Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by Her-2 status and trastuzumab treat- ment: an institutional-based review[J], J Clin Oncol, 2010, 28(1): 92-98.
  • 3Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against Her-2 for metastatic breast can- cer that overexpresses Her-2[J]. N Engl J Med, 2001, 344,(11): 783-792.
  • 4Robert N, Leyland-Jones B, Asmar L ,et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paditaxel in women with HER-2-overexpressing metastatic breast cancer[J].J Clin Oncol, 2006, 24(18):2786-2792.
  • 5Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and Safety of Trastuzumab as a Single Agent in first-line treatment of Her-2-overexpressing metastatic breast cancer[J], J Clin Oncol, 2002, 20(3):719-726.
  • 6Romond EH, Perez E, Bryant J, et al. Trastuzumab plus Adjuvant chemotherapy for operable Her2-posifive breast cancer[J]. N EnglJ Med, 2005, 353(16):1673-1684.
  • 7Perez EA, Suman VJ, Davidson NE, et al. Sequential versus concur- rent trastuzumab in adjuvant chemotherapy for breast cancer[J]. J Clin Oncol, 2011, 29(34):4491-4497.
  • 8Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin[J]. Clin Cancer Res, 2011, 17(20):6417-6427.
  • 9Petersdorf S, Kopecky K, Smart RK, et al. Preliminary results of Southwest Oncology Group Study S0106: An international intergroup phase 3 randomized trial comparing the addition of gemmzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemmzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia[J]. Blood, 2009, 114:790.
  • 10Junttila TT, Li G, Parsons K, et al. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer[J]. Breast Can- cer Res Treat, 2011, 128(2):347-356.

同被引文献65

  • 1LAPUSAN S, VIDRIALES MB, THOMAS X, et al. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate,in adult pa- tients with relapsed/refractory acute myeloid leukemia [J]. Invest New Drug, 2012, 30(3): 1121-1131.
  • 2VENGHATERI JB, GUPTA TK, VERMA PJ, et al. Ansamitocin P-3 Depolymerizes Microtubules and Induces Apoptosis by Binding to Tubulin at the Vinblastine Site[J]. Plos one, 2013,8(10): e75182.
  • 3GERBER HP, KOEHN FE, ABRAHAM RT. The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics [J]. Nat Prod Rep, 2013, 30(5): 625-639.
  • 4SIEVERS EL, SENTER PD. Antibody-drug conjugates in cancer therapy [J]. Annu Rev Med, 2013, 64:15-29.
  • 5TAFT F, BRUNJES M, KNOBLOCH T. Timing of the Δ 10,12-Δ 11,13 double bond bigration during ansamitocin biosynthesis in actinosyrmema pretiosum[J]. J Am Chem Soc, 2009, 131(11): 3812-3813.
  • 6WU Yingying, KANG Qianjin, SHANG Guangdong, et al. N-methylation of the amide bond by methyltransferase asm10 in ansamitocin biosynthe- sis[J]. Chembioehem, 2011, 12(11): 1759-1766.
  • 7YU TW, BAI LQ, CLADE D, et al. The biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from Actinosynnema pretio- sum[J]. P Natl Aead Sci USA, 2002, 99(12): 7968-7973.
  • 8LIN Jinxia, BAI Linquan, DENG Zixin. Enhanced production of ansamitocin P-3 by addition of isobutanol in fermentation of Actinosyrmema pretiosum [J]. Bioresource Technol, 2011, 102 (2): 1863-1868.
  • 9BANDI S, KIM Y J, CHANG YK, et al. Construction of asm2 Deletion Mutant of Actinosynnema pretiosum and Medium Optimization for Ansamitocin P-3 Production Using Statistical Approach[J]. J Mierobiol Biotechn, 2006, 16(9): 1338-1346.
  • 10HUANG JX, YANG JS, WEI Y. Dynamic models for polyhydroxybu- tyrate fermentation process [J]. Chem Eng-New York, 2005, 33 (1): 44-47.

引证文献6

二级引证文献17

中国肿瘤临床
2013年 第19期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部